Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
60 hot topic(s) found with the query "Venous thromboembolism"

Lipoprotein(a), platelet function and cardiovascular disease.
Harpreet S Bhatia et al. Nat Rev Cardiol 2023 11 (Posted: Nov 11, 2023 4PM)

From the abstract: " Lipoprotein(a) (Lp(a)) independently contributes to atherothrombosis through several mechanisms, including putative antifibrinolytic properties. However, genetic association studies and experimental studies have not demonstrated an association between high Lp(a) levels in the plasma and the risk of venous thromboembolism or clot properties, respectively."

Identifying individuals at extreme risk of venous thromboembolism using polygenic risk scores.
Michael Chong et al. Nature genetics 2023 3 (3) 358-360 (Posted: Mar 18, 2023 3PM)

Current risk assessment and treatment strategies for venous thromboembolism (VTE) consider genetic factors only in a limited way. New work shows a more pervasive role of common variants in VTE risk, inspiring genetic predictors that surpass and complement individual clinical risk factors and monogenic thrombophilia testing.

Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism.
Ghouse Jonas et al. Nature genetics 2023 1 (Posted: Jan 22, 2023 8AM)

We report a genome-wide association study of venous thromboembolism (VTE) incorporating 81,190?cases and 1,419,671?controls sampled from six cohorts. We identify 93?risk loci, of which 62 are previously unreported. Many of the identified risk loci are at genes encoding proteins with functions converging on the coagulation cascade or platelet function. A VTE polygenic risk score (PRS) enabled effective identification of both high- and low-risk individuals.

Association of Supernumerary Sex Chromosome Aneuploidies With Venous Thromboembolism.
Berry Alexander S F et al. JAMA 2023 1 (3) 235-243 (Posted: Jan 18, 2023 1PM)

In this retrospective multicohort study that included 642?544 adult participants, the incidence of a VTE diagnosis among those with an additional sex chromosome compared with those with 2 sex chromosomes was 1.3% per person-year compared with 0.25% per person-year, respectively, in one cohort, and 0.42% per person-year compared with 0.11% per person-year, respectively, in the other cohort. These differences were statistically significant.

Epidemiology and prevention of venous thromboembolism.
Lutsey Pamela L et al. Nature reviews. Cardiology 2022 10 (Posted: Oct 20, 2022 6AM)

Venous thromboembolism (VTE) surveillance systems are lacking, but VTE is estimated to affect one to two individuals per 1,000 person-years in Europe and the USA, with lower rates in other regions. Risk factors for VTE are varied, and include triggers (acute and subacute), basal risk factors (demographic, behavioural, anthropometric and genetic) and acquired clinical risk factors. Numerous complications can occur after a VTE event, and quality of life can decrease.

Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19
J Xie et al, JAMA Internal Medicine, August 18, 2022 (Posted: Aug 18, 2022 1PM)

What is the 30-day acute risk of venous thromboembolism (VTE) among ambulatory patients with COVID-19, and what are the clinical and genetic risk factors predisposing them to developing post–COVID-19 VTE? In this retrospective cohort study of 18?818 outpatients with COVID-19 and 93?179 propensity score–matched noninfected participants, a higher VTE incidence was observed in the former (hazard ratio, 21.42); however, this risk was considerably attenuated among the fully vaccinated, after breakthrough infection. Older age, male sex, obesity, no vaccination or partial vaccination, and inherited thrombophilia were independent risk factors for COVID-19–associated VTE.

Shared genetic etiology and causality between COVID-19 and venous thromboembolism: evidence from genome-wide cross trait analysis and bi-directional Mendelian randomization study
X Huang et al, MEDRXIV, May 27, 2022 (Posted: May 28, 2022 11AM)

Shared genetic etiology and causality between COVID-19 and venous thromboembolism: evidence from genome-wide cross trait analysis and bi-directional Mendelian randomization study
X Huang et al, MEDRXIV, May 21, 2022 (Posted: May 23, 2022 7AM)

Genetic risk and incident venous thromboembolism in middle-aged and older adults following 1 Covid-19 vaccination
J Xie et al, MEDRXIV, April 18, 2022 (Posted: Apr 19, 2022 6AM)

Using data from the UK Biobank, which contains in-depth genotyping data and linked vaccination and health outcomes information, we generated a polygenic risk score (PRS) using 299 genetic variants identified from a previous large genome-wide association study. We prospectively assessed associations between PRS and incident VTE after first and the second-dose vaccination separately. The PRS was significantly associated with a higher risk of VTE (HR per 1 SD increase in PRS, 1.41 (95% CI 1.15 to 1.73) in 28 days and 1.36 (95% CI 1.22 to 1.52) in 90 days). Similar associations were found after stratification by vaccine type, in the two-dose cohort and across the historical unvaccinated cohorts.

Thromboembolism and bleeding after covid-19
FK Ho et al, BMJ April 6, 2022 (Posted: Apr 07, 2022 10AM)

It is now clear from meta-analyses of case series, cohort studies, and self-controlled case series that the risk of venous thromboembolism is increased after SARS-CoV-2 infection. However, two important questions remain: for how long post-infection is the risk increased, and does mild infection also increase risk? A new paper addresses these questions by applying two complementary study designs to data from several Swedish registries.

Venous Thromboembolism in Ambulatory Covid-19 patients: Clinical and Genetic Determinants
J Xie et al, MEDRXIV, March 22, 2022 (Posted: Mar 23, 2022 9AM)

Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations
KK Lim et al, Pharmacogenomics Journal, June 15, 2021 (Posted: Jun 16, 2021 8AM)

The ten eligible studies, all model-based, examined heterogeneous interventions and comparators. Findings varied widely; testing was cost-saving in two base-cases, cost-effective in four, not cost-effective in three, dominated in one. Of 22 model variables that changed decisions about cost-effectiveness, effectiveness/relative effectiveness of the intervention was the most frequent, albeit of poor quality.

COVID-19 vaccines for patients with haematological conditions
C Sun, Lancet Hematological Diseases, March 31, 2021 (Posted: Apr 02, 2021 8AM)

The trajectory of COVID-19 in patients with benign hematological conditions such as haemoglobinopathy, haemophilia, pre-existing arterial or venous thromboembolism, and autoimmune cytopenia is relatively unknown, but as in the general population, is influenced by age and comorbidities.

Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap
D Klarin et al, Nature Genetics, November 1, 2019 (Posted: Nov 02, 2019 7AM)

We identified 22 previously unknown loci, bringing the total number of venous thromboembolism-associated loci to 33, and subsequently fine-mapped these associations. We developed a genome-wide polygenic risk score for venous thromboembolism that identifies 5% of the population at an equivalent risk to factor V Leiden p.R506Q and prothrombin G20210A mutations

Prevention and Management of Venous Thromboembolism
JD Paul et al, JAMA, September 23, 2019 (Posted: Sep 24, 2019 9AM)

Venous Thromboembolism (VTE) Recurrence Risk Stratification in the Perioperative Setting: High risk include VTE within past 3 months, Protein C or S or antithrombin deficiency, Antiphospholipid antibody syndrome, Multiple thrombophilic abnormalities.

Risk and Risk Factors Associated With Recurrent Venous Thromboembolism Following Surgery in Patients With History of Venous Thromboembolism
B Nemeth et al, JAMA Network Open, May 10, 2019 (Posted: May 11, 2019 0PM)

VTE Training and Education for Healthcare Professionals
CDC, 2018 (Posted: Dec 17, 2018 10AM)

Family history of venous thromboembolism in the paediatric population: The need for a standardized definition.
Hau Anna et al. Thrombosis research 2018 Nov 17391-95 (Posted: Dec 04, 2018 10AM)

Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG)
S Zhang et al, Genetics in Medicine, October 9, 2018 (Posted: Oct 09, 2018 2PM)

Pregnant? Learn about blood clots.
Brand (Posted: Sep 25, 2018 10AM)

Should we screen hereditary thrombophilia testing in patients with provoked/unprovoked venous thromboembolism?
Ulas Turgay et al. International journal of cardiology 2018 Jul (Posted: Jul 25, 2018 8AM)

Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism.
Hugon-Rodin Justine et al. Thrombosis and haemostasis 2018 Apr (Posted: Apr 04, 2018 11AM)

Are you at risk for clots?
A family history of blood clots can increase a person?s risk. Brand (Posted: Mar 12, 2018 11AM)

Advances in predicting venous thromboembolism risk in children.
Rühle Frank et al. British journal of haematology 2017 Dec (Posted: Dec 31, 2017 8AM)

Hereditary Thrombophilia in Trauma Patients with Venous Thromboembolism: Is Routine Screening Necessary?
Cannon Kathleen A et al. The journal of trauma and acute care surgery 2017 Nov (Posted: Dec 06, 2017 9AM)

Thrombophilia Testing and Venous Thrombosis
JM Connors, NEJM, Sep 2017 (Posted: Sep 20, 2017 5PM)

Thrombophilia testing results in patients with a first venous thromboembolic event: should the selection criteria for testing be revisited?
Hirmerova Jana et al. International angiology : a journal of the International Union of Angiology 2017 Apr (2) 167-173 (Posted: Jun 06, 2017 7AM)

Thrombophilia Testing in Provoked Venous Thromboembolism- A Teachable Moment
A Gupta et al, JAMA Internal Medicine, June 2017 (Posted: Jun 06, 2017 7AM)

Venous Thromboembolism: Know the Risks, Signs & Symptoms of Blood Clots
Brand (Posted: May 17, 2017 2PM)

Personal Stories of People Living with Deep Vein Thrombosis and Pulmonary Embolism
CDC Social Media Brand (Posted: May 17, 2017 2PM)

Are You at Risk for Blood Clots?
Brand (Posted: Mar 06, 2017 3PM)

Inherited Thrombophilia
S Collins, Genome Magazine, January 2017 (Posted: Feb 09, 2017 4PM)

The Appropriateness and Cost of Thrombophilia Panel Testing: It’s Complicated
S Bowen et al, CDC Blog Post, December 15, 2016 Brand (Posted: Dec 15, 2016 3PM)

Having Surgery? Take Steps to Prevent Blood Clots!
C Hooper, HHS Blog Post, August 22, 2016 (Posted: Aug 24, 2016 1PM)

Stop the Clot, Spread the Word
New Campaign Materials on Blood Clots and Hospitalization (Posted: Aug 13, 2016 10AM)

African Ancestry and Dangerous Blood Clots
R Lewis, PLOS Blogs, June 30, 2016 (Posted: Jun 30, 2016 1PM)

CDC Challenge Winners!
CDC champions for success in preventing healthcare-associated blood clots. Brand (Posted: Apr 05, 2016 10AM)

Deep Vein Thrombosis and Pulmonary Embolism (DVT/PE) are often underdiagnosed and serious, but preventable medical conditions.
Brand (Posted: Apr 05, 2016 9AM)

Personal Stories of Deep Vein Thrombosis
CDC Flickr Album (Posted: Mar 19, 2016 0PM)

Blood Clot: It Happened to Her, Don’t Let It Happen to You
Craig Hooper, HHS Blog post, October 20, 2015 (Posted: Oct 29, 2015 10AM)

JAMA Patient Page: Deep Vein Thrombosis
AE Thompson, JAMA May 26, 2015 (Posted: Jun 01, 2015 1PM)

Venous thrombosis
A. Wolberg et al. Nature Reviews Disease Primers May 2015 (Posted: May 18, 2015 2PM)

Familial transmission of venous thromboembolism: a cohort study of 80?214 Swedish adoptees linked to their biological and adoptive parents.
Zöller Bengt et al. Circ Cardiovasc Genet 2014 Jun (3) 296-303 (Posted: Apr 25, 2015 11AM)

Economic Analysis of Thrombo inCode, a Clinical-Genetic Function for Assessing the Risk of Venous Thromboembolism.
Rubio-Terrés C et al. Appl Health Econ Health Policy 2015 Feb 5. (Posted: Mar 11, 2015 9AM)

CDC Information: March is Deep Vein Thrombosis Awareness Month
Are you at risk? Brand (Posted: Feb 25, 2015 0PM)

Blood Clots and Travel: What You Need to Know
Brand (Posted: Feb 25, 2015 0PM)

Deep vein thrombosis/pulmonary embolism are often underdiagnosed and serious, but preventable medical conditions
Brand (Posted: Feb 25, 2015 0PM)

Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).
Pabinger I et al. J. Thromb. Haemost. 2015 Jan (1) 17-22 (Posted: Feb 20, 2015 10AM)

Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis.
Wang Jiarong et al. Thromb. Res. 2014 Dec (6) 1241-8 (Posted: Feb 20, 2015 10AM)

Genetics in thrombophilia. An update.
Reitsma P H et al. Hamostaseologie 2015 Feb 10. (1) 47-51 (Posted: Feb 20, 2015 10AM)

Predicting venous thrombosis in women using a combination of genetic markers and clinical risk factors.
Bruzelius M et al. J. Thromb. Haemost. 2015 Feb (2) 219-27 (Posted: Feb 20, 2015 10AM)

Impact of thrombophilic genes mutations on thrombosis risk in Egyptian nonmetastatic cancer patients.
Wahba Mona Ahmed et al. Blood Coagul. Fibrinolysis 2015 Jan 6. (Posted: Feb 20, 2015 10AM)

Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study.
Kovac Mirjana et al. Eur. J. Intern. Med. 2015 Jan (1) 63-7 (Posted: Feb 20, 2015 10AM)

Polymorphisms in thrombophilic genes are associated with deep venous thromboembolism in an Iranian population.
Farajzadeh Malak et al. Meta Gene 2014 Dec 505-13 (Posted: Feb 20, 2015 10AM)

Single nucleotide polymorphisms in interleukin-6 and their association with venous thromboembolism.
Yadav Umesh et al. Mol Med Rep 2015 Jan 26. (Posted: Feb 20, 2015 10AM)

Venous thromboembolism in heart transplantation: Should we consider genetic predisposition?
Dolapoglu Ahmet et al. J. Heart Lung Transplant. 2014 Dec 18. (Posted: Feb 20, 2015 10AM)

Economic Analysis of Thrombo inCode, a Clinical-Genetic Function for Assessing the Risk of Venous Thromboembolism.
Rubio-Terrés C et al. Appl Health Econ Health Policy. 2015 Feb 5. (Posted: Feb 20, 2015 10AM)

Prevalence of Hereditary Thrombophilia in Patients Older Than 75 Years With Venous Thromboembolism Referred for Thrombophilia Screening.
Siguret Virginie et al. J. Gerontol. A Biol. Sci. Med. Sci. 2015 Feb 9. (Posted: Feb 19, 2015 6PM)

Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism.
Lewis Deborah A et al. Thromb. Res. 2015 Feb 7. (Posted: Feb 19, 2015 6PM)

Pulmonary Embolism
From NHLBI health topic site Brand (Posted: Jan 11, 2014 11AM)

What Is Pulmonary embolism (PULL-mun-ary EM-bo-lizm), or PE, is a sudden blockage in a lung artery. The blockage usually is caused by a blood clot that travels to the lung from a vein in the leg. A clot that forms in one part of the body and travels in the bloodstream to another part of the body is called an embolus (EM-bo-lus). PE is a serious condition that can: ?Damage part of your lung because of a lack of blood flow to your lung tissue. This damage may lead to pulmonary hypertension (increased pressure in the pulmonary arteries). ?Cause low oxygen levels in your blood. ?Damage other organs in your body because of a lack of oxygen. If a blood clot is large, or if there are many clots, PE can cause death. Overview PE most often is a complication of a condition called deep vein thrombosis (DVT). In DVT, blood clots form in the deep veins of the body?most often in the legs. These clots can break free, travel through the bloodstream to the lungs, and block an artery. Deep vein clots are not like clots in veins close to the skin's surface. Those clots remain in place and do not cause PE. Outlook The exact number of people affected by DVT and PE isn't known. Estimates suggest these conditions affect 300,000 to 600,000 people in the United States each year. If left untreated, about 30 percent of patients who have PE will die. Most of those who die do so within the first few hours of the event. The good news is that a prompt diagnosis and proper treatment can save lives and help prevent the complications of PE. Other Names ?Venous thromboembolism (VTE). This term is used for both pulmonary embolism and deep vein thrombosis.


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP